API

ACEMETACINE is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of osteoarthritis, rheumatoid arthritis, lower back pain, and relieving post-operative pain.

Products still subject to third-party patent protection might be available solely for R&D purposes.

As a novel potassium-competitive acid blocker, VONOZOPRAN FUMARATE may provide reversible acid suppression by preventing K+ from binding to gastric H+/K+-ATPase. It has been clinically used for the short-term treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease and Helicobacter pylori (H. pylori) infection.

Products still subject to third-party patent protection might be available solely for R&D purposes.

MOSAPRIDE CITRATE is a gastroprokinetic agent that acts as a selective 5HT4 agonist. The major active metabolite of mosapride, known as M1, additionally acts as a 5HT3 antagonist, which accelerates gastric emptying throughout the whole of the gastrointestinal tract in humans.

Products still subject to third-party patent protection might be available solely for R&D purposes.

PRANLUKAST HYDRATE is a cysteinyl leukotriene receptor-1 antagonist. It is widely used in Japan.

Products still subject to third-party patent protection might be available solely for R&D purposes.

SUGAMMADEX SODIUM is a medication for the reversal of neuromuscular blockade induced by rocuronium and vecuronium in general anaesthesia. It is the first selective relaxant binding agent (SRBA).

Products still subject to third-party patent protection might be available solely for R&D purposes.

ROXULITINIB PHOSPHATE is a medication used for the treatment of intermediate or high-risk myelofibrosis.

Products still subject to third-party patent protection might be available solely for R&D purposes.